Q-omics provides the consensus-scored ZNF675 profile across patient tissues and cancer cell-line models. ZNF675 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ZNF675 is differentially expressed in 9, with the highest sampling consensus in BLCA. Additionally, ZNF675 RNA expression shows 20,840 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and BLCA as cancer lineages where ZNF675 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF675 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF675 survival associations across molecular data types. ZNF675 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF675 RNA expression–survival associations across cancer types. High ZNF675 expression shows unfavorable associations in UVM, UCEC and LIHC, but favorable associations in KIRC, UCS and BRCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ZNF675 RNA expression.
This table summarizes ZNF675 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF675. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF675 shows higher tumor expression in BLCA, UCEC, BRCA, LIHC, LUAD and KIRP. The BLCA box plot shows higher ZNF675 RNA expression in tumor versus normal tissue (log2 FC = +1.413, t-test p < 0.001).
This table shows molecular features associated with ZNF675 in patient tissues and cancer cell lines. In patient samples, ZNF675 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF675 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SOFT_TISSUE.
